KVD818

KVD818 is an investigational oral small molecule drug developed by KalVista Pharmaceuticals. It is a plasma kallikrein inhibitor designed primarily for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. The mechanism of action involves inhibition of plasma kallikrein, an enzyme that plays a key role in the generation of bradykinin, which mediates vascular permeability and swelling in HAE. KVD818 aims to reduce or prevent HAE attacks by blocking this pathway. The drug has entered Phase I clinical trials as part of KalVista's portfolio targeting oral treatments for HAE and other protease-related diseases.